Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Director Sells $54,250.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $8.68, for a total value of $54,250.00. Following the completion of the sale, the director directly owned 103,242 shares of the company’s stock, valued at $896,140.56. The trade was a 5.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Stock Down 1.4%

NASDAQ:SOPH traded down $0.12 during trading hours on Wednesday, hitting $8.53. 232,020 shares of the company traded hands, compared to its average volume of 241,759. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The company has a market cap of $715.58 million, a PE ratio of -7.42 and a beta of 0.96. The firm’s 50-day simple moving average is $6.33 and its 200-day simple moving average is $5.37. SOPHiA GENETICS SA has a one year low of $3.10 and a one year high of $8.85.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. Equities analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 4th quarter valued at approximately $49,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the first quarter valued at approximately $50,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on SOPH shares. HC Wainwright lifted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. BTIG Research increased their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.